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Introduction
Structural changes of cartilage and bone resulting from 
arthritis were recognized in the mid-nineteenth century: 
witness Baker’s description of bone cysts as a protective 
mechanism for the joint [1]. Th   ese cysts were considered 
pressure-regulated escape mechanisms for the inﬂ  amed 
synovium into the marrow space [2]. Damage of the 
periarticular bone and the articular cartilage are now 
known to be hallmarks of arthritis, symbolizing the des-
truc  tive potential of chronic inﬂ   ammation. A deeper 
insight into the mechanism of structural changes trig-
gered by chronic joint diseases such as rheumatoid 
arthritis (RA), psoriatic arthritis (PsA), and ankylosing 
spondylitis (AS) is essential for developing therapies that 
can arrest, prevent, and even reverse bone and cartilage 
changes. More speciﬁ  c interventions to treat inﬂ  amma-
tion in arthritis, for example monoclonal antibodies and 
soluble receptors, have added considerably to our know-
ledge of arthritic structural damage. In particular, the 
blockade of TNF has shown that eﬀ  ective anti-inﬂ  am-
matory therapy can preserve joint structure, which is 
critical to maintaining joint function.
RA, PsA, and AS diﬀ  er substantially in their patterns of 
bone and cartilage damage. Th  ese  diﬀ  erences are at least 
partly based on the variable capability to form new bone, 
which may reﬂ  ect a skeletal response to inﬂ  ammation. 
Goals and strategies to prevent and treat structural 
damage should therefore also diﬀ  er. In the present article, 
we summarize the mechanistic concepts of structural 
damage in these three major joint diseases, we review the 
achievements of TNF blockers – in particular, their 
contribution to under  standing structural damage – and 
we discuss unanswered questions and future frontiers in 
the management of bone and cartilage damage in RA, 
PsA, and AS.
Rheumatoid arthritis
Original thoughts on structural damage in RA
RA is the prototype of a destructive arthritis. Th  e  disease 
directly leads to joint damage, with only a few signs of 
repair. Tradition  ally, structural damage in RA has been 
identiﬁ   ed using conventional radiography to detect 
cortical bone ero  sions, joint space narrowing, and peri-
articular osteoporosis. Imaging has shown unequivocally 
that there is a net loss of cartilage and bone in patients 
with RA. In particular, the presence of bone erosions has 
emerged as an indicator of irreversible damage resulting 
from a continuous inﬂ  ammatory attack of the synovial 
membrane on bone. Synovitis is of pivotal importance for 
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© 2011 BioMed Central Ltdbone and cartilage damage in RA. Both the severity of 
inﬂ  ammation – whether measured by C-reactive protein, 
the number of swollen joints, or the duration of morning 
stiﬀ  ness – and the duration of inﬂ  ammation have there-
fore emerged as important predictors of structural damage 
in RA [3,4]. Autoantibodies such as rheumatoid factor and 
anti-citrullinated protein antibodies, and  – in close 
connection to anti-citrullinated protein anti  bodies – the 
presence of the shared epitope in the HLA-DRB1 region, 
also predict the risk for bone erosions, which is probably 
related to a close association between autoantibodies and 
the chronicity of arthritis [5,6]. Molecularly, the tight 
interaction between inﬂ  ammation and bone/cartilage loss 
in RA is explained by the production of enzymes such as 
aggrecanases and matrix metalloproteinases, which 
degrade articular cartilage and bone as well as molecules 
that support the diﬀ  erentiation of osteoclasts [7].
Bone and cartilage loss has traditionally been a main 
diagnostic, monitoring, and outcome parameter in 
patients with RA in both clinical trials and routine clinical 
practice. Bone and cartilage damage is rapid and dynamic 
after disease onset and aﬀ  ects the majority of RA patients 
within the ﬁ  rst year [8]. Th   e severity of bone and cartilage 
damage in RA is closely related to physical function in 
RA patients, suggesting that structural damage indeed 
impairs physical function [9-11]. Finally, eﬀ  ective control 
of inﬂ  ammation by conventional disease-modifying anti-
rheumatic drugs (DMARDs) or combination therapies of 
DMARDs and glucocorticoids retards structural damage 
in RA. Structure-sparing eﬀ  ects have been documented 
for methotrexate (MTX), sulfasalazine, and leﬂ  unomide 
individually and in combination [12-15]. It is not clear, 
however, whether MTX, sulfasalazine, leﬂ  unomide, and 
hydroxychloroquine directly aﬀ   ect bone and cartilage 
damage, or indirectly beneﬁ   t joints by reducing 
inﬂ  ammation.
Novel insights gained from use of TNF blockers in RA
Th   e introduction of TNF blockers as a therapeutic option 
in RA has challenged our view not only of synovitis but 
also of progression of structural damage. One of the most 
consistent eﬀ  ects of TNF-blocking agents in RA patients 
is a profound and sustained inhibition of bone erosion. In 
fact, all ﬁ  ve TNF blockers approved for the therapy of RA 
strongly retard or even arrest structural damage [16-24]. 
Th   is strong structure-preserving eﬀ  ect is partially due to 
profound and rapid control of inﬂ  ammation. Also appar-
ent, however, is that anti-resorptive eﬀ  ects may occur 
despite a lack of clinical response to a TNF blocker [24]. 
TNF-blocking agents thus combine a strong anti-
inﬂ   ammatory poten  tial, which controls synovitis, with 
direct protection of bone and cartilage (Table 1).
In this context it is noteworthy that TNF is an impor  tant 
inducer of osteoclast formation and thus is a key molecular 
link between inﬂ  ammation and bone damage [7]. Addition 
of TNF to monocyte cultures challenged with macrophage 
colony-stimulating factor and receptor activator of NF-κB 
ligand (molecules that activate osteo  clasts, which are the 
cells involved in bone resorption) enhances the formation 
of osteoclasts, and overexpres  sion of TNF in mice entails 
increased formation of osteo  clasts resulting in systemic 
bone loss as well as local bone erosions [25-27]. With 
respect to cartilage damage, TNF also is an inducer of 
matrix enzymes such as aggrecanases and metallo  protein-
ases, particularly MMP-1, MMP-2, and MMP-3, which are 
produced by synovial ﬁ   broblasts, neutrophils, and 
chondrocytes and degrade the cartilage matrix. A speciﬁ  c 
protective eﬀ  ect of TNF blockade on articular cartilage is 
therefore conceivable; current evidence is circumstantial, 
however, and is not backed by suﬃ   cient  data.  Direct 
assessment of the cartilage of small peripheral joints is still 
technically challenging and, to date, TNF blockers have 
shown little if any eﬀ  ect on the cartilage [28].
Future needs and unanswered questions in RA
TNF-blocking agents have undoubtedly enriched our 
therapeutic options for blocking structural damage in 
RA. Nonetheless, several aspects remain enigmatic. Th  e 
lack of adequate spontaneous joint repair and better 
strategies to induce joint repair will be a central ﬁ  eld of 
future basic and clinical research. Indeed, any potential 
for erosion self-healing is still poorly characterized. 
Exami  na  tion of sequential radiographs from clinical 
studies suggest that individual lesions can improve, 
especially when there is no or reduced swelling in the 
joint [29]. Other studies indicate that joint repair and 
erosion healing is rare despite eﬀ  ective therapy with TNF 
inhibitors [30]. More detailed imaging techniques such as 
ultrasound, magnetic resonance imaging (MRI), and 
computed tomography may provide better information in 
the future. Reﬁ  lling bone erosions might be an important 
clinical goal, if the technique could restore ligament and 
enthesial function. If such repair proves possible, it must 
be followed by an assessment of joint function.
Future frontiers in RA also will include the interaction 
between inﬂ  ammation and structural progression. With 
improved treatment options and tighter control of 
inﬂ  ammation, more patients will have low disease activity 
or will be in remission. Even patients who are considered 
to be in clinical remission, however, can progress in 
structural damage [31-33]. How much residual synovitis 
is necessary to allow structural progression is not yet 
clear. Even subclinical synovitis may suﬃ   ce to trigger a 
progression of cartilage and bone damage followed by a 
decrease in joint function. Improved detection of 
synovitis with ultrasound and MRI may allow a better 
understanding of the eﬀ  ect of subclinical synovitis on 
joint structure [34-38].
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Original thoughts on structural damage in PsA
For a long time, PsA was not recognized as a speciﬁ  c entity 
but rather was considered a subtype of RA that occurred 
in combination with skin psoriasis. Even after formal 
recognition, PsA was considered to be a mild disease with 
a benign course. Research in PsA has long lagged behind 
RA research in terms of diagnosis, prog  nosis, and 
treatment. Th  e diagnostic criteria of Moll and Wright, 
although not based on patient-derived data and omitting 
key features of PsA such as nail disease and dactylitis, were 
widely used [39]. Th   ese criteria did not mitigate diﬃ   culties 
classifying study patients, and there  fore research remained 
limited. Th  e Classiﬁ  cation Criteria for Psoriatic Arthritis 
now provide sensitive and speciﬁ  c classiﬁ  cations for PsA 
[40]. Research is still limited in early disease, however, as 
the Classiﬁ  cation Criteria for Psoriatic Arthritis were built 
on data from patients with long-standing disease.
PsA patients suﬀ  er  signiﬁ   cant joint damage and 
disability over time. In accordance with RA, PsA is an 
erosive disease leading to the resorption of cortical bone. 
In addition, however, PsA shows morphological features 
discordant with RA; that is, the formation of bony spurs 
along the insertion sites of the entheses (enthesiophytes) 
[41]. Depending on the scoring system used, the damage 
and disability in PsA is less pronounced than in RA [42] 
or is equal to RA [43] with equivalent disease duration. 
Patients with RA and patients with PsA have similar 
functional and quality-of-life impairment [42].
Data from longitudinal cohort studies have helped 
identify severe disease with poor structural outcome. 
High inﬂ  ammatory activity and joint damage at the time 
of presentation are considered the most important 
predictors of future clinical and radiologic joint damage 
[44,45]. For instance, a high erythrocyte sedimentation 
rate at baseline and the presence of joint swelling suggest 
a poor prognosis with respect to structural outcome 
[44,46]. Moreover, patients with axial disease have more 
severe peripheral joint disease [47].
Previously, therapies for PsA were borrowed from RA, 
often without any speciﬁ   c studies to assess their 
eﬀ   ectiveness in this diﬀ  erent  condition.  Th  ere is a 
surprising lack of randomized controlled trials evaluating 
the impact of DMARD therapy on PsA. Observational 
studies of patients receiving traditional DMARD therapy, 
however, have shown little control of structural damage. 
Observational controlled studies with sulfasalazine and 
gold have shown no reduction in long-term joint damage 
[48,49]. An observational cohort study of 23 patients who 
received 2-year MTX therapy concluded that MTX 
treatment did not reduce radiologic progression com-
pared with matched controls [50]. However, a more 
recent analysis of the same cohort  – but without 
controls – has suggested otherwise [51]. Chandran and 
colleagues found that since the mid-1990s MTX had 
been prescribed earlier and in higher doses, resulting in a 
signiﬁ  cant decline in actively inﬂ  amed joint count and 
psoriasis, and some decrease in progression of radiologic 
joint damage [51]. Th   ere is no direct evidence, however, 
showing that DMARD therapy aﬀ  ects joint damage.
Novel insights gained from use of TNF blockers in PsA
TNF blockers have provided the ﬁ  rst  evidence-based 
treatment for PsA with proven eﬀ  ects on arthritis, skin 
disease, enthesitis, dactylitis, and spinal disease. Th  ese 
agents are highly eﬀ  ective in PsA, and they are the ﬁ  rst 
with proven eﬃ   cacy at reducing both active joint in-
ﬂ   am  mation and radiographic damage in randomized 
con  trolled trials of PsA [52-56] (Table 2). Th  e vast 
majority of PsA patients treated with TNF blockers 
showed no worsening in radiographic damage scores 
[52,55-58]. Since the scoring systems used for the 
assessment of radiographic damage of PsA are the same 
as those used for RA, however, our knowledge about 
TNF-blocker eﬀ  ects on structural damage are conﬁ  ned 
to the erosive component of the disease, and it is 
unclear whether these agents also aﬀ  ect enthesiophyte 
formation.
Table 1. Key studies of TNF-blocker therapy in rheumatoid arthritis, 52-week follow-up
Therapy  Disease stage  Reference  Primary outcome  Radiologic outcome
Infl  iximab  RA  Smolen and colleagues [16]  ACR20  Modifi  ed TSS
Infl  iximab  Early RA  Smolen and colleagues [17]  ACR20  Modifi  ed TSS
Etanercept  Early RA  Bathon and colleagues [18]  ACR20  TSS
Etanercept  RA  Klareskog and colleagues [19]  ACR20  Modifi  ed TSS
Etanercept  Early RA  Kekow and colleagues [20]  ACR20  Modifi  ed TSS
Adalimumab  Early RA  Breedveld and colleagues [21]  ACR50  Modifi  ed TSS
Adalimumab  RA  Keystone and colleagues [22]  ACR20  Modifi  ed TSS
Golimumab  RA  Kremer and colleagues [23]  ACR50  Modifi  ed TSS
Certolizumab  RA  Keystone and colleagues [24]  ACR20  Modifi  ed TSS
ACR20/50, American College of Rheumatology 20%/50% improvement; RA, rheumatoid arthritis; TSS, total Sharp score.
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Th   e next step in investigating structural damage in PsA is 
to search for evidence of a direct link between inﬂ  am-
mation and joint damage. Imaging studies have elegantly 
demonstrated this link in RA, using a combination of 
MRI, ultrasound, and conventional radiography [63,64]. 
Such data, however, are currently unavailable in PsA. 
Also of interest is the link between inﬂ  ammation and 
new bone formation, which is typical for PsA but is not 
encountered in RA.
As in RA, we must evaluate the use of anti-inﬂ   am ma tory 
therapies in PsA and investigate their ability to prevent 
long-term damage. If there is a direct link between 
inﬂ  ammation and damage in PsA, then tight control of 
inﬂ  ammation may arrest damage in PsA – as has been 
demonstrated in RA [65,66]. Does this also apply to 
enthesiophyte formation? Th  e answer is unclear and at 
least doubtful, as the formation of bony spurs in AS is not 
inﬂ  uenced by TNF blockade. In this context it also will be 
important to deﬁ   ne treatment targets based on either 
clinical outcomes or imaging. For instance, a new clinical 
measure for minimal disease activity encompassing 
remission and low disease activity has been developed, but 
needs further testing in prospective studies [67].
Ankylosing spondylitis
Original thoughts on structural damage in AS
Low back pain is the earliest clinical manifestation for AS 
and indicates inﬂ  ammation in the sacroiliac joints and 
the spine, which can be identiﬁ  ed by MRI [68]. Disease 
progression is characterized by ongoing back pain 
lead  ing to skeletal changes in the sacroiliac joints, 
identiﬁ  able by plain radiography. Th   e diagnosis of AS has 
long hinged upon evidence of structural damage; the 
modiﬁ   ed New York criteria require the presence of 
radiographic sacro  iliitis to give a deﬁ  nite diagnosis [69]. 
Studies have shown that it can take up to 10 years for 
these changes to become visible on plain radiographs 
[70], but radiographs are still widely used in established 
disease. Skeletal changes in the sacroiliac joints in AS are 
characterized by the concomitant presence of catabolic 
changes such as erosions as well as new bone formation 
leading to progressive ankylosis.
Spinal syndesmophytes are thought to appear at a later 
stage [71], although this hypothesis remains unclear. Th  is 
concept is supported by two facts: patients in the pre-
radiographic stages of AS can suﬀ  er just as much pain 
and stiﬀ  ness as those already diagnosed [72]; and patients 
treated early with TNF blockers demonstrate a better 
response than those treated later in their disease course 
[73]. Treatment should be started in the early stages of 
the disease process, before irreversible structural damage 
has occurred; that is, before the modiﬁ   ed New York 
criteria are fulﬁ  lled. With the new classiﬁ  cation criteria 
of spondylarthritis it will be possible to start eﬀ  ective 
medication earlier, which may yield a considerable 
change of the disease course in the future.
Spinal structural changes in AS are quantiﬁ  ed radio-
graphically using the modiﬁ  ed Stoke Ankylosing Spondy-
litis Spine Score, which grades the cervical and lumbar 
spine for the presence of erosions, squaring, sclerosis, 
syndesmophytes, and bony bridging at each site [74]. Th  e 
Table 2. Key studies of TNF-blocker therapy in psoriatic arthritis
  Outcomes reported
    Primary  Radiologic      Dactylitis    Function       CRP/
Therapy  Published  study  outcome  outcomes  Joint Skin  Nail   Enthesitis   QoL  Pain  EMS  Fatigue  ESR
Infl   iximab  Antoni  and    ACR20  at  mvdH-SS  at x  x  x  x  x  x    x
  colleagues [59],  week 16  week 50
 Kavanaugh  and 
 colleagues  [52]   
Infl   iximab  Antoni  and      ACR20  at  mvdH-SS  at x  x  x  x  x  x  x  x
  colleagues [60],  week 14  weeks 24 and 54
  van der Heijde and 
 colleagues  [56]   
Etanercept  Mease  and  PsARC  at    NA  x  x      x  x    x
  colleagues [61]  week 12
Etanercept  Mease  and  ACR20  at    mTSS  at  x  x      x  x    x
  colleagues [58]  week 12  months 6 and 12
Adalimumab  Mease and  ACR20 at   mTSS at  x  x    x  x  x  x      x 
  colleagues [54]  week 12  week 24 
Golimumab  Kavanaugh  and ACR20  at    NA  x x x x x x         
  colleagues [62]  week 14 
ACR20, American College of Rheumatology 20% improvement; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate, EMS, early morning stiff  ness; mvdH-SS, 
modifi  ed van der Heijde–Sharp score; mTSS, modifi  ed total Sharp score; NA, not available; PsARC, Psoriasis Arthritis Response Criteria; QoL, quality of life.
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Spondylitis Spine Score to assess the thoracic spine [75], 
which is the most commonly involved area as shown on 
MRI studies [76], limits the score’s sensitivity to assess 
change. Spooren  berg and colleagues have demonstrated 
that a minimum 2 years of follow-up is necessary to 
reliably detect radio  graphic change, meaning that studies 
assessing radio  graphic damage must be of signiﬁ  cantly 
longer duration than similar studies in peripheral 
arthritis [77].
Traditionally, AS has been treated with regular physio-
therapy and nonsteroidal anti-inﬂ  ammatory  drugs 
(NSAIDs). Indeed, the only evidence for a reduction in 
radiographic progression in patients with AS is from a 
trial of continuous versus on-demand treatment with 
NSAIDs. Patients on continuous NSAID therapy had 
signiﬁ  cantly reduced radiographic progression compared 
with those who took the therapy only when serious 
symptoms were present [78]. Both groups experienced 
similar eﬀ  ects on symptoms, inﬂ  ammation, and spinal 
mobility.
Novel insights gained from use of TNF blockers in AS
Th  e advent of TNF inhibitors has greatly improved the 
treat  ment options for AS. Th  ey allow treatment of 
patients with severe disease who do not fully respond to 
NSAIDs. Th   ree TNF blockers are licensed and approved 
worldwide, and a fourth blocker (golimumab) was 
recently approved. Criteria have been set by various regu-
latory bodies for their use [79,80].
Similar eﬃ     cacy has been found for all of the TNF 
blockers, although studies have consistently shown that 
patients relapse with cessation of therapy [81,82] 
(Table 3). Despite the strong anti-inﬂ  ammatory eﬀ  ect of 
TNF blockers in AS, these agents do not inﬂ  uence new 
bone formation in AS [83-85]. Only one small study 
showed reduced radiographic progression in AS patients 
treated with inﬂ  iximab in comparison with a historical 
cohort, but these results have to be considered with 
caution as the baseline Bath Ankylosing Spondylitis 
Disease Activity Index score was diﬀ  erent between the 
groups [86,87].
Th   is lack of a structure-sparing eﬀ  ect of TNF blockers 
in AS unravels the diﬀ   erent pathophysiologic mecha-
nisms underlying RA, PsA, and AS. RA is typically 
charac  ter  ized by bone erosion, whereas the main 
structural out  come in AS is bony spur formation based 
on bone formation.
Radiographic damage at baseline is a major predictor of 
future radiographic progression; in particular, the 
presence of syndesmophytes or ankylosis [86,88]. MRI-
evident sacroiliitis and positivity for HLA-B27 have been 
shown to predict the development of radiographic sacro-
iliitis in patients with early inﬂ  ammatory back pain at 
8-year follow-up, with a sensitivity and speciﬁ  city of 77% 
each [89]. MRI has now been incorporated into the new 
Assessment of Spondyloarthritis International Society 
classiﬁ  cation criteria for axial spondyloarthritis [90].
Th   e relationship between inﬂ  ammation and new bone 
formation in AS remains unclear. Recent MRI studies 
Table 3. Key studies of TNF-blocker therapy in ankylosing spondylitis
 Outcomes  reported
    Primary  Radiologic  Follow-         CRP/
Therapy Published  study  outcome  outcome  up  BASDAI  BASFI  BASMI  QoL  EMS  Fatigue  ESR
Infl  iximab  Braun and colleagues   50% improvement  mSASSS  5 years  x  x  x  x  x    x
  [96-100]  in BASDAI at week 12   
Infl  iximab  Marzo-Ortega and   Change in BASDAI  MRI  30 weeks  x  x    x  x    x
  colleagues [101]  at weeks 4,   infl  ammatory
   10,  30  lesions
Infl  iximab  van der Heijde and   ASAS 20 at  mSASSS  8 years  x  x  x  x  x  x  x
  colleagues [83,102]  week 24 
Etanercept  Davis and colleagues   ASAS 20 at  mSASSS  16 years  x  x  x    x    x
  [103-105], van der Heijde   week 12   
  and colleagues [84]     
Etanercept  Calin and colleagues   ASAS 20 at  mSASSS  8 years  x  x  x    x    x
  [106], Dijkmans and   week 12   
 colleagues  [107]     
Adalimumab  van der Heijde and   ASAS 20 at  NA  24 weeks  x  x  x  x  x    x
  colleagues [108]  week 12 
Golimumab  Inman and colleagues   ASAS 20 at  NA  24 weeks  x  x  x  x  x    x
 [109]  week  14 
ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate; EMS, early morning stiff  ness; MRI, 
magnetic resonance imaging; mSASSS, modifi  ed Stoke Ankylosing Spondylitis Spine Score; NA, not applicable; QoL, quality of life.
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known as Romanus lesions or bone edema) predict the 
development of syndesmophytes [91]. Th   ese studies also 
demonstrated formation of syndesmophytes at the exact 
location of resolved inﬂ  ammatory lesions. One explana-
tion is that there may be persistent mild inﬂ  ammation 
not detected by MRI. Th   e discovery that syndesmophytes 
were more likely to develop at the sites of resolved corner 
inﬂ   ammatory lesions rather than those of persistent 
lesions, however, led to the TNF brake hypothesis. Th  is 
hypothesis suggests that TNF triggers pathways leading 
to new bone formation, but that while there is active 
inﬂ  ammation TNF suppresses new bone formation via 
dickkopf-1 (a regulator of joint remodeling) [92]. When 
patients are treated with TNF inhibitors, therefore, 
inﬂ  ammation resolves, the brake is released, and tissue 
repair and new bone formation occur [91]. Th  is  process 
may account for radio  graphic progression in patients 
who appear to otherwise respond well to anti-TNF 
therapy. Evidence for uncoup  ling between inﬂ  ammation 
and new bone formation is supported by a mouse model 
of spondyloarthritis, which showed no eﬀ  ect  of 
etanercept on the severity and incidence of joint 
ankylosis [93].
An independent study of patients receiving anti-TNF 
agents found that an inﬂ  amed vertebral edge at baseline 
had a threefold increased risk to develop a syndesmo-
phyte than a non-inﬂ   amed vertebral edge [94]. Th  ese 
results contrast with those of Maksymowych and 
colleagues [91]. MRI scans were performed only at 
baseline and 2 years, however, so it is possible that 
inﬂ  ammation had occurred and resolved between scans. 
Bennett and colleagues described fatty Romanus lesions 
in the spine, which they suggest may be the post-
inﬂ   ammatory phase between osteitis on MRI and 
sclerotic bone formation on radiographs [95].
Future needs and unanswered questions in AS
Despite the eﬃ   cacy of TNF blockers for symptomatic 
control and improved quality of life in patients with AS, 
the lack of eﬃ   cacy for radiographic progression is note-
worthy. Longer studies may be needed, because the 
process linking inﬂ  ammation and new bone formation is 
slow. Eﬀ  ective suppression of inﬂ  ammation may thus still 
reduce radio  graphic progression.
Additional research is needed to analyze whether 
progression is due to persistent, low-grade inﬂ  ammation 
or to the release of the TNF brake once inﬂ  ammation is 
eﬀ  ectively treated. Th   e answer to this question will guide 
future therapies. Perhaps a dual approach will be 
necessary: one therapy to treat inﬂ  ammation and another 
to prevent new bone formation.
MRI has facilitated the study of early disease, and the 
treatment response of patients in the pre-radiographic 
stage may help determine whether suppression of inﬂ  am-
mation can prevent early onset of structural damage. 
Since not all patients with MRI-evident sacroiliitis develop 
AS, however, treatment must be carefully targeted. Lastly, 
there is the issue of late presentation of AS patients to 
rheumatologists, which can be improved by the 
education of both doctors and patients.
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